Alpine Select AG (ALPNE)
Market Closed
10 Aug, 15:20
SIX 
8. 80
CHF 0
0%
- Market Cap
- Div Yield
0 Volume
8.8 CHF
Previous Close Want to track ALPNE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ALPNE closed yesterday higher at 8.8 CHF, an increase of 0% from Friday's close, completing a monthly increase of 0% or 0 CHF. Over the past 12 months, ALPNE stock gained 0%.
ALPNE is not paying dividends to its shareholders.
The last earnings report, released on Mar 17, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.14%, based on the last three reports.
Alpine Select AG has completed 1 stock splits, with the recent split occurring on Jul 25, 2017.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).
ALPNE Chart
Alpine Select AG (ALPNE) FAQ
What is the stock price today?
The current price is 8.80 CHF.
On which exchange is it traded?
Alpine Select AG is listed on SIX.
What is its stock symbol?
The ticker symbol is ALPNE.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Alpine Select AG ever had a stock split?
Alpine Select AG had 1 splits and the recent split was on Jul 25, 2017.
Alpine Select AG Profile
| SIX Exchange | US Country |
Overview
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, established in 2007. The company specializes in the field of immunotherapy, focusing on the development of innovative treatments for autoimmune and inflammatory diseases through advanced protein engineering technologies. Alpine Immune Sciences is dedicated to addressing unmet medical needs by pioneering novel therapeutics designed to modulate the immune system.
Products and Services
The company's development pipeline showcases a range of immunotherapy candidates aimed at treating various autoimmune and inflammatory conditions, each leveraging unique mechanisms of action:
- Povetacicept: Currently in Phase 2 clinical trials, Povetacicept is a pioneering dual B cell cytokine antagonist. This candidate seeks to offer a new approach for treating a spectrum of autoimmune and inflammatory diseases by targeting key pathways involved in the immune response.
- Acazicolcept: Acazicolcept is in the preclinical trial phase and functions as a dual inhibitor targeting the CD28 and ICOS T cell costimulatory pathways. This mechanism is particularly focused on the treatment of systemic lupus erythematosus, aiming to provide a novel therapeutic option for patients suffering from this challenging condition.
- RUBY-3: RUBY-3 has successfully completed Phase 1 clinical trials and is designed for the treatment of glomerulonephritis. This therapeutic candidate represents Alpine Immune Sciences' commitment to developing innovative solutions for kidney-related inflammatory diseases.
- RUBY-4: Having completed Phase 1 clinical trials, RUBY-4 is aimed at addressing cytopenias. This program highlights the company's efforts to expand its pipeline into therapies that could potentially treat a range of hematological disorders.
Contact Information
Address: 188 East Blaine Street
Phone: 206 788 4545
Website: https://www.alpineimmunesciences.com
